Immuno-Oncology | Specialty

FDA Approves Frontline Pembrolizumab Regimen for Squamous NSCLC

October 31st 2018

The FDA has approved first-line pembrolizumab for use in combination with carboplatin and either paclitaxel or nab-paclitaxel for the treatment of patients with metastatic squamous non–small cell lung cancer.

Dr. Amin on Toxicities With Immunotherapy/TKI Combinations in RCC

October 30th 2018

Asim Amin, MD, PhD, director of immunotherapy, Levine Cancer Institute, discusses how to manage toxicities associated with immunotherapy and tyrosine kinase inhibitor combinations in renal cell carcinoma.

Dr. Hamid on a Retrospective Analysis of Pembrolizumab in Melanoma

October 30th 2018

Omid Hamid, MD, director of Research and Immuno-Oncology at The Angeles Clinic, discusses a retrospective analysis of pembrolizumab (Keytruda) in patients with melanoma.

Dr. Rudin Discusses the Success of Immunotherapy in SCLC

October 30th 2018

Charles M. Rudin, MD, PhD, chief, Thoracic Oncology Service, co-director, Druckenmiller Center for Lung Cancer Research, Sylvia Hassenfeld Chair in Lung Cancer Research, Memorial Sloan Kettering Cancer Center, discusses the success of immunotherapy in small cell lung cancer.

Expert Discusses Durvalumab and Future of Immunotherapy in NSCLC

October 28th 2018

Neil Morganstein, MD, discusses the intriguing PACIFIC results and the future role of immunotherapy in non–small cell lung cancer.

Immunotherapy Breaks Through in Breast Cancer

October 27th 2018

Peter Schmid, MD, PhD, shares the results of IMpassion130 and discussed his thoughts on the future of immunotherapy in breast cancer.

Dr. Herbst on Long Term Survival With Pembrolizumab in NSCLC

October 25th 2018

Roy S. Herbst, MD, PhD, Ensign Professor of Medicine and professor of pharmacology, chief of Medical Oncology, Yale Cancer Center and Smilow Cancer Hospital; associate director for Translational Research, Yale Cancer Center; Disease Aligned Research Team (DART) Leader, Thoracic Oncology Program, Yale Cancer Center, discusses long-term survival of patients with non–small cell lung cancer (NSCLC) treated with pembrolizumab (Keytruda).

Expert Anticipates Bright Future for Immunotherapy in HNSCC

October 25th 2018

Ezra Cohen, MD, discusses the future role of immunotherapy in the treatment of patients with head and neck squamous cell carcinoma.

Dr. Sweis on Immunotherapy Combinations in Kidney Cancer

October 25th 2018

Randy F. Sweis, MD, instructor of medicine, University of Chicago Medicine, discusses immunotherapy combinations in kidney cancer.

Dr. Weber on Discontinuing Immunotherapy in Melanoma

October 25th 2018

Jeffrey S. Weber, MD, PhD, deputy director and co-director of the Melanoma Program, NYU Langone’s Perlmutter Cancer Center, 2016 Giant of Cancer Care® in Melanoma, discusses when to discontinue immunotherapy in patients with melanoma.

Borghaei Shares Insight on Immunotherapy in NSCLC

October 25th 2018

Hossein Borghaei, DO, MS, discusses immunotherapy selection for the treatment of patients with non–small cell lung cancer.

Pembrolizumab Active in BCG-Unresponsive NMIBC

October 24th 2018

An interim analysis of an ongoing single-arm open-label phase II study showed encouraging antitumor activity with pembrolizumab (Keytruda) in patients with high-risk nonmuscle invasive bladder cancer that is unresponsive to Bacillus Calmette-Guérin.

Dr. Amin on Next Steps With Immunotherapy in Advanced RCC

October 24th 2018

Asim Amin, MD, PhD, director of immunotherapy, Levine Cancer Institute, discusses next steps with immunotherapy in the treatment of patients with advanced renal cell carcinoma.

The Rapidly Changing Landscape in RCC Therapy: What Future Research May Hold

October 24th 2018

The poor long-term survival outcomes for patients with advanced renal cell carcinoma have prompted intensive clinical research aimed at developing novel therapeutic options addressing unmet needs.

Dr. Kim Discusses the Primary Efficacy Results From the B-F1RST Trial in NSCLC

October 23rd 2018

Edward S. Kim, MD, chair, Department of Solid Tumor Oncology, Levine Cancer Institute, discusses the primary efficacy results from the B-F1RST trial in non–small cell lung cancer (NSCLC).

Immunotherapy Research Key to Moving SCLC Field Forward

October 23rd 2018

Ramsey N. Asmar, MD, discusses recent advances and next steps in small cell lung cancer.

Neoadjuvant Nivolumab Plus Ipilimumab Active in dMMR Early-Stage Colon Cancer

October 23rd 2018

First results from a study of neoadjuvant ipilimumab plus nivolumab in patients with early-stage colon cancer found a major pathologic response achieved in all 7 patients with mismatch repair deficient tumors.

FDA Extends Review Period for Frontline Nivolumab/Ipilimumab in TMB-High NSCLC

October 22nd 2018

The FDA has added 3 months to the review period for the combination of nivolumab plus low-dose ipilimumab for the frontline treatment of patients with advanced non–small cell lung cancer with tumor mutational burden ≥10 mutations per megabase.

Engineered Anti-MAGE-A T-Cells Show Early Promise

October 21st 2018

Genetically engineered T-cells targeting a common tumor antigen appeared safe and demonstrated some evidence of antitumor activity in a first-in-human clinical evaluation.

Dr. Rosenberg on Dosing of Nivolumab Plus Ipilimumab in Bladder Cancer

October 20th 2018

Jonathan E. Rosenberg, MD, medical oncologist, chief, Genitourinary Medical Oncology Service, Memorial Sloan Kettering Cancer Center, discusses dosing for the combination of nivolumab (Opdivo) and ipilimumab (Yervoy) in patients with metastatic urothelial carcinoma at the 2018 ESMO Congress.